|
|
Post by seanismorris on May 3, 2020 21:38:57 GMT -5
I wonder how much of patients reaction to taking Afrezza is mental... powder phobia.
Would the instance of cough lessen if Afrezza (technosphere) was called a compound, formulation, or solution?
If I inhale a powder (dust, flour, etc) I think I should cough, so I do...
|
|
|
|
Post by casualinvestor on May 4, 2020 10:15:55 GMT -5
My pessimistic view is that GILD does not care what kind of burden taking their drug involves (cleaning a nebulizer after each use), as long as they are first to market.
Also, I found this on compassionate use dosing:
I'm not sure how well that works with TS
|
|
|
|
Post by peppy on May 4, 2020 11:01:42 GMT -5
|
|
|
|
Post by mango on May 4, 2020 11:29:10 GMT -5
Highlights• SARS-CoV-2 RdRp shares 97% sequence identity to SARS. • SARS-CoV-2 RdRp model is built to study different inhibitors. • Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir can bind tightly the RdRp of SARS-CoV-2. • Setrobuvir, YAK, and IDX-184 can be used as potent compounds against SARS-CoV-2 RdRp.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 4, 2020 12:36:30 GMT -5
That aerosol treatment comes with a significant treatment burden and many drawbacks and limitations compared to what MannKind offers. I seriously doubt GILD will go the nebulizer route fro Remdesivir. www.youtube.com/watch?v=s8oYm8WrAOw |
|
|
|
Post by nylefty on May 4, 2020 22:38:48 GMT -5
|
|
|
|
Post by peppy on May 5, 2020 4:44:06 GMT -5
We all know Mannkind offers great products! But what do they offer Shareholders? I seriously doubt GILD will go the nebulizer route fro Remdesivir. www.youtube.com/watch?v=s8oYm8WrAOw almost laughable. |
|
|
|
Post by mango on May 5, 2020 13:40:30 GMT -5
We all know Mannkind offers great products! But what do they offer Shareholders? I seriously doubt GILD will go the nebulizer route fro Remdesivir. www.youtube.com/watch?v=s8oYm8WrAOw The treatment burden associated with the Altera Inhalation System is significant, as well as are the limitations and drawbacks associated with it. It is on par with the outdated Tyvaso Inhalation System. Requires batteries, requires the nebulizer to be connected to a controller via a wiring cable, requires a lot of time to assemble, use, and then break down, requires a proper set and setting to use it, requires daily disinfecting, and so on and so on. MannKind's inhalation system looks like alien technology in comparison. This further underscores MannKind's importance to filling a serious unmet medical need for people living with CF —a next generation inhalation system that is user-friendly, portable, discrete, convenient, precise, effective, ultra-fast and very quick to administer, even on-the-go. MannKind needs to push for the CF treatments in the pipeline and stop stalling them, IMO.  |
|
|
|
Post by mytakeonit on May 5, 2020 15:00:46 GMT -5
Actually, the Altera inhalation system looks more alien ... especially with that dome cover. And how many treatments a day is necessary with this system? Is it with every meal like Afrezza? Looks like a no brainer on which system I would choose.
But, that's mytakeonit
|
|
|
|
Post by mango on May 5, 2020 15:18:12 GMT -5
Actually, the Altera inhalation system looks more alien ... especially with that dome cover. And how many treatments a day is necessary with this system? Is it with every meal like Afrezza? Looks like a no brainer on which system I would choose. But, that's mytakeonit ---------INDICATIONS AND USAGE------------------ CAYSTON is a monobactam antibacterial indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia. (1) --------------DOSAGE AND ADMINISTRATION------------- • Administer one dose (one single use vial and one ampule of diluent) 3 times a day for 28 days. (2.1)• Use dose immediately after reconstitution. (2.2) • Administer only with the Altera® Nebulizer System. Do not administer with any other type of nebulizer. (2.3) |
|
|
|
Post by mytakeonit on May 5, 2020 15:26:11 GMT -5
So it seems that as soon as the unit is cleaned and dried ... then it's time for your next dose. Holy crap Batman !
But, that's mytakeonit
|
|
|
|
Post by matt on May 6, 2020 7:00:44 GMT -5
Does it even make sense to make an inhaled form as Remdesivir is not a frequently administered drug like insulin. The present trials are dosed 200mg on Day 0 and 100mg for a further 5 to 10 days. If a patient is in the hospital being treated for COVID, they almost certainly have an IV line in which case an injectable formulation is a non-issue. There may be other conditions for which a different dosing regimen may be indicated, and therefore have some attraction as an inhaled drugs, but not for COVID.
|
|
|
|
Post by peppy on May 6, 2020 7:04:59 GMT -5
Does it even make sense to make an inhaled form as Remdesivir is not a frequently administered drug like insulin. The present trials are dosed 200mg on Day 0 and 100mg for a further 5 to 10 days. If a patient is in the hospital being treated for COVID, they almost certainly have an IV line in which case an injectable formulation is a non-issue. There may be other conditions for which a different dosing regimen may be indicated, and therefore have some attraction as an inhaled drugs, but not for COVID. "Gilead is in discussions with some of the world’s leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the developing world through at least 2022. The company is also negotiating long-term voluntary licenses with several generic drugmakers in India and Pakistan to produce remdesivir for developing countries. Gilead will provide appropriate technology transfers to facilitate this production. Finally, the company is in active discussions with the Medicines Patent Pool, which Gilead has partnered with for many years, to license remdesivir for developing countries. Close coordination of remdesivir manufacturing will be critical. This is why Gilead is working to build a consortium of manufacturing partners – to bring efforts together to help maximize global supply. Producing the drug requires scarce raw materials, with their own lengthy production time, and specialized manufacturing capabilities with limited global capacity. Any disruption to the supply chain impacting these scarce raw materials and other manufacturing inputs could reduce the amount of remdesivir produced and increase the time it takes to do so. " A Hail Mary |
|
|
|
Post by bill on May 6, 2020 10:36:31 GMT -5
Does it even make sense to make an inhaled form as Remdesivir is not a frequently administered drug like insulin. The present trials are dosed 200mg on Day 0 and 100mg for a further 5 to 10 days. If a patient is in the hospital being treated for COVID, they almost certainly have an IV line in which case an injectable formulation is a non-issue. There may be other conditions for which a different dosing regimen may be indicated, and therefore have some attraction as an inhaled drugs, but not for COVID. "Gilead is in discussions with some of the world’s leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the developing world through at least 2022. The company is also negotiating long-term voluntary licenses with several generic drugmakers in India and Pakistan to produce remdesivir for developing countries. Gilead will provide appropriate technology transfers to facilitate this production. Finally, the company is in active discussions with the Medicines Patent Pool, which Gilead has partnered with for many years, to license remdesivir for developing countries. Close coordination of remdesivir manufacturing will be critical. This is why Gilead is working to build a consortium of manufacturing partners – to bring efforts together to help maximize global supply. Producing the drug requires scarce raw materials, with their own lengthy production time, and specialized manufacturing capabilities with limited global capacity. Any disruption to the supply chain impacting these scarce raw materials and other manufacturing inputs could reduce the amount of remdesivir produced and increase the time it takes to do so. " A Hail Mary Good points, but since Remdesivir seems to be most effective if taken early, an inhaled version might turn out to be the most popular form of administration since it could be done without hospitalization and it could be given as soon as a person is diagnosed with COVID-19 versus waiting until they are hospitalized--which wouldn't be "early." |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 6, 2020 11:10:12 GMT -5
The treatment burden associated with the Altera Inhalation System is significant, as well as are the limitations and drawbacks associated with it. It is on par with the outdated Tyvaso Inhalation System. Requires batteries, requires the nebulizer to be connected to a controller via a wiring cable, requires a lot of time to assemble, use, and then break down, requires a proper set and setting to use it, requires daily disinfecting, and so on and so on. MannKind's inhalation system looks like alien technology in comparison. This further underscores MannKind's importance to filling a serious unmet medical need for people living with CF —a next generation inhalation system that is user-friendly, portable, discrete, convenient, precise, effective, ultra-fast and very quick to administer, even on-the-go. MannKind needs to push for the CF treatments in the pipeline and stop stalling them, IMO. Do you realize if/WHEN TreT gets approved how many BP will be calling MNKD to inquire about Technosphere and their PIPELINE? This is what Matt was talking about with an Embarrassment of Riches. MNKD has to get TreT approved. |
|
